Search research articles
Contact Us
Filters
Showing results (91-100 of 125) with videos related to
Page
of 13
Sort By:
Eclinicalmedicine
|
March 10, 2023
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
Neha Korde, Elizabet Tavitian, Donna Mastey, et al.
Blood Cancer Journal
|
May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Karthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Leukemia & Lymphoma
|
October 1, 2016
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone
Elisabet E Manasanch, Carlos Fernández de Larrea, Adriana Zingone, et al.
American Journal of Hematology
|
January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach
Matthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
JCO Oncology Practice
|
September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses
Issam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances
|
April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
Issam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
Malin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
Blood Advances
|
March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing
Carlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances
|
May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Benjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
American Journal of Hematology
|
March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasone
Neha Korde, Donna Mastey, Elizabet Tavitian, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 125) with videos related to
Sort By:
Page
of 13
Eclinicalmedicine
|
March 10, 2023
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
Neha Korde, Elizabet Tavitian, Donna Mastey, et al.
Blood Cancer Journal
|
May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Karthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Leukemia & Lymphoma
|
October 1, 2016
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone
Elisabet E Manasanch, Carlos Fernández de Larrea, Adriana Zingone, et al.
American Journal of Hematology
|
January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach
Matthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
JCO Oncology Practice
|
September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses
Issam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances
|
April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
Issam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
Malin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
Blood Advances
|
March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing
Carlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances
|
May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Benjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
American Journal of Hematology
|
March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasone
Neha Korde, Donna Mastey, Elizabet Tavitian, et al.
Page
of 13